Suspended

UPtimum-PsAReal-world Effectiveness and Treatment Patterns of Upadacitinib in Monotherapy or Used in Combination With Methotrexate in Active Psoriatic Arthritis Patients

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
Who is being recruted

Arthritis+10

+ Bone Diseases

+ Joint Diseases

Over 18 Years
+6 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Cohort

Tracking disease incidence in order to identify risk factors and understand disease progression over time.
Observational
Study Start: December 2022
See protocol details

Summary

Principal SponsorAbbVie
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: December 15, 2022

Actual date on which the first participant was enrolled.

Psoriatic arthritis (PsA) is a chronic, immune-mediated, systemic disease affecting less than 1% of people with variations by parts of the world, and around 20%-30% of participants with psoriasis. Upadacitinib (RINVOQ) is approved drug for the treatment of adult participants with active PsA in Europe. Approximately 450 adult participants who are prescribed Upadacitinib by their physician in accordance with local label will be enrolled in 4 countries in Europe: France, Germany, Greece and Italy. Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 24 months. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Official TitleReal-world Effectiveness and Treatment Patterns of Upadacitinib in Monotherapy or Used in Combination With Methotrexate in Active Psoriatic Arthritis Patients
NCT05616871
Principal SponsorAbbVie
Last updated: January 28, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

450 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Cohort

These studies follow a group of individuals with common characteristics (such as a condition or birth year) over a specific period to study health outcomes or exposures.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

ArthritisBone DiseasesJoint DiseasesMusculoskeletal DiseasesPsoriasisSkin DiseasesSpinal DiseasesSpondylitisArthritis, PsoriaticSkin and Connective Tissue DiseasesSkin Diseases, PapulosquamousSpondylarthritisSpondylarthropathies

Criteria

4 inclusion criteria required to participate
Confirmed diagnosis of active psoriatic arthritis (PsA) whose peripheral involvement justifies the prescription of upadacitinib upon judgement of the treating physician.
Physician decision on participant treatment with upadacitinib must have been reached prior to and independently of recruitment in the study.
Upadacitinib prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies.
Participants able to understand and communicate with the investigator and comply with the requirements of the study.
2 exclusion criteria prevent from participating
Participation in a clinical trial of an investigational drug, concurrently or within the last 30 days.
Prior treatment with upadacitinib.

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives

Study Objectives

Primary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 88 locations

Suspended

Centre Hospitalier Régional d'Orléans - Hôpital de la Source /ID# 252530

Orléans, FranceOpen Centre Hospitalier Régional d'Orléans - Hôpital de la Source /ID# 252530 in Google Maps
Suspended

AP-HP - Groupe Hospitalier 10e - Hopital Lariboisiere /ID# 252526

Paris, France
Suspended

AP-HP - Hopital Saint-Antoine /ID# 252627

Paris, France
Suspended

Centre Hospitalier Universitaire de Nice - Hôpital Pasteur /ID# 252536

Nice, France
Suspended88 Study Centers
UPtimum-PsA | Real-world Effectiveness and Treatment Patterns of Upadacitinib in Monotherapy or Used in Combination With Methotrexate in Active Psoriatic Arthritis Patients | PatLynk